In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats

Obesity

Volumn 21, Issue 12, 2013, Pages 2522-2529

  Nemanich, Samuel ^a   Rani, Sudheer ^a   Shoghi, Kooresh ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PALMITIC ACID C 11; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL RAT; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; IN VIVO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RAT; SKELETAL MUSCLE; ZUCKER DIABETIC FATTY RAT;

RATTUS;

ADIPOSE TISSUE, BROWN; ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; LIVER; MUSCLE, SKELETAL; OBESITY; PPAR GAMMA; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES;

EID: 84889637971     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20378     Document Type: Article

References (40)

1. Kahn BB, Flier JS,. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
2. Flier JS,. Diabetes. The missing link with obesity? Nature 2001; 409: 292-293.
3. Wilson PW,. Diabetes mellitus and coronary heart disease. Endocrinol Metab Clin North Am 2001; 30: 857-881.
4. Phillips DI, Caddy S, Ilic V, et al. Intramuscular triglyceride and muscle insulin sensitivity: Evidence for a relationship in nondiabetic subjects. Metabolism 1996; 45: 947-950.
5. Fruhbeck G, Becerril S, Sainz N, Garrastachu P, Garcia-Velloso MJ,. BAT: A new target for human obesity? Trends Pharmacol Sci 2009; 30: 387-396.
6. Kawashita NH, Brito MN, Brito SR, et al. Glucose uptake, glucose transporter GLUT4, and glycolytic enzymes in brown adipose tissue from rats adapted to a high-protein diet. Metabolism 2002; 51: 1501-1505.
7. Nicholls DG, Locke RM,. Thermogenic mechanisms in brown fat. Physiol Rev 1984; 64: 1-64.
8. Pilkis SJ, Granner DK,. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 1992; 54: 885-909.
9. McGarry JD,. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
10. Shoghi KI, Finck BN, Schechtman KB, et al. In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: Differential efficacy of metformin and rosiglitazone monotherapy. Circ Cardiovasc Imaging 2009; 2: 373-381.
11. Shoghi KI, Gropler RJ, Sharp T, et al. Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: A small-animal PET investigation. J Nucl Med 2008; 49: 1320-1327.
12. Bonen A, Holloway GP, Tandon NN, et al. Cardiac and skeletal muscle fatty acid transport and transporters and triacylglycerol and fatty acid oxidation in lean and Zucker diabetic fatty rats. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1202-R1212.
13. Day C,. Thiazolidinediones: A new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192.
14. Tai Y-C, Ruangma A, Rowland D, et al. Performance evaluation of the microPET focus: A third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005; 46: 455-463.
15. Dence CS, Herrero P, Schwarz SW, et al. Imaging Myocardium Enzymatic Pathways with Carbon-11 Radiotracers. Methods in Enzymology. San Diego, California, Academic Press; 2004. p. 286-315.
16. Shoghi K,. Hybrid image-blood-sampling input function with a Bezier linker for quantification of microPET data. J Nucl Med Meet Abstr 2007; 48 (MeetingAbstracts-2): 402P-b.
17. Williams KV, Bertoldo A, Mattioni B, Price JC, Cobelli C, Kelley DE,. Glucose transport and phosphorylation in skeletal muscle in obesity: Insight from a muscle-specific positron emission tomography model. J Clin Endocrinol Metab 2003; 88: 1271-1279.
18. Ferre P, Leturque A, Burnol AF, Penicaud L, Girard J,. A method to quantify glucose utilization in vivo in skeletal muscle and white adipose tissue of the anaesthetized rat. Biochem J 1985; 228: 103-110.
19. Patlak CS, Blasberg RG,. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
20. DeGrado TR, Wang S, Rockey DC,. Preliminary evaluation of 15-[18F]Fluoro-3-oxa-pentadecanoate as a PET tracer of hepatic fatty acid oxidation. J Nucl Med 2000; 41: 1727-1736.
21. Southworth R, Parry CR, Parkes HG, Medina RA, Garlick PB,. Tissue-specific differences in 2-fluoro-2-deoxyglucose metabolism beyond FDG-6-P: A 19F NMR spectroscopy study in the rat. NMR Biomed 2003; 16: 494-502.
22. Holloway GP, Benton CR, Mullen KL, et al. In obese rat muscle transport of palmitate is increased and is channeled to triacylglycerol storage despite an increase in mitochondrial palmitate oxidation. Am J Physiol Endocrinol Metab 2009; 296: E738-E747.
23. Luiken JJ, Arumugam Y, Dyck DJ, et al. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 2001; 276: 40567-40573.
24. Guiducci L, Liistro T, Burchielli S, et al. Contribution of organ blood flow, intrinsic tissue clearance and glycaemia to the regulation of glucose use in obese and type 2 diabetic rats: A PET study. Nutr Metab Cardiovasc Dis 2011; 21: 726-732.
25. Williams KV, Price JC, Kelley DE,. Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance: A dose-response assessment using positron emission tomography. Diabetes 2001; 50: 2069-2079.
26. Leonard BL, Watson RN, Loomes KM, Phillips AR, Cooper GJ,. Insulin resistance in the Zucker diabetic fatty rat: A metabolic characterisation of obese and lean phenotypes. Acta Diabetol 2005; 42: 162-170.
27. Nawano M, Oku A, Ueta K, et al. Hyperglycemia contributes insulin resistance in hepatic and adipose tissue but not skeletal muscle of ZDF rats. Am J Physiol Endocrinol Metab 2000; 278: E535-E543.
28. Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM,. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001; 50: 1294-1300.
29. Hardman MJ, Hull D,. The action of insulin on brown adipose tissue in vivo. J Physiol 1972; 221: 85-92.
30. Guerra C, Navarro P, Valverde AM, et al. Brown adipose tissue-specific insulin receptor knockout shows diabetic phenotype without insulin resistance. J Clin Invest 2001; 108: 1205-1213.
31. Iozzo P, Hallsten K, Oikonen V, et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care 2003; 26: 2069-2074.
32. Cypess AM, Kahn CR,. Brown fat as a therapy for obesity and diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 143-149.
33. Hallsten K, Virtanen KA, Lonnqvist F, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med 2004; 21: 1280-1287.
34. Hofmann C, Lorenz K, Colca JR,. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 1991; 129: 1915-1925.
35. Blaak EE,. Basic disturbances in skeletal muscle fatty acid metabolism in obesity and type 2 diabetes mellitus. Proc Nutr Soc 2004; 63: 323-330.
36. Coort SL, Coumans WA, Bonen A, van der Vusse GJ, Glatz JF, Luiken JJ,. Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. J Lipid Res 2005; 46: 1295-1302.
37. Benton CR, Holloway GP, Campbell SE, et al. Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria. J Physiol 2008; 586: 1755-1766. PMCID: 2375706.
38. Sreenan S, Keck S, Fuller T, Cockburn B, Burant CF,. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am J Physiol 1999; 276: E1119-E1129.
39. Lessard SJ, Rivas DA, Chen ZP, et al. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance. Diabetes 2007; 56: 1856-1864.
40. de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863-1871.